Eton Pharmaceuticals (ETON) Return on Capital Employed (2018 - 2025)

Eton Pharmaceuticals has disclosed Return on Capital Employed across 8 years of filings, most recently posting 1.6% for Q4 2025.

• Return on Capital Employed for Q4 2025 came in at 1.6%, up 62.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 1.6% (up 62.0% YoY), and the FY2025 annual result was 2.1%, up 26.0% from the prior year.
• Return on Capital Employed came in at 1.6% for Q4 2025 at Eton Pharmaceuticals, down from 1.5% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 39.49% in Q3 2023 to a low of 56.76% in Q2 2022.
• The 5-year median for Return on Capital Employed is 7.2% (2021), against an average of 16.3%.
• Across the five-year window, Return on Capital Employed soared 18434 bps in 2021 and sank 8090 bps in 2024, its largest moves.
• Eton Pharmaceuticals' Return on Capital Employed stood at 6.65% in 2021, then slumped by 69 bps to 11.26% in 2022, then jumped by 31 bps to 7.74% in 2023, then soared by 71 bps to 2.22% in 2024, then increased by 28 bps to 1.6% in 2025.
• The last three Return on Capital Employed figures came in at 1.6% (Q4 2025), 1.5% (Q3 2025), and 1.82% (Q2 2025), per Business Quant data.